---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132760"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:09:58.008179+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kymera reports positive Phase 1 data for oral STAT6 degrader KT-621; >90% STAT6 degradation at low doses

## Summary
- SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.
- MAD: complete STAT6 degradation in blood and skin at doses ≥50 mg; safety undifferentiated from placebo with no SAEs.
- Th2 biomarkers: median TARC -37%, Eotaxin-3 -63% at Day 14, comparable or superior to dupilumab in healthy volunteers.
- KT-621 well-tolerated: no TRAEs in >1 subject, no severe AEs, no discontinuations, no clinically relevant lab/ECG changes.
- Next steps: Phase 1b AD data Q4 2025; Phase 2b AD start Q4 2025, asthma Q1 2026, enabling parallel Phase 3 readiness.

## SEC filing metadata
- accession: 0001193125-25-132760
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525132760/0001193125-25-132760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525132760/d57872d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132760
- JSON: https://secwatch.observer/filing/0001193125-25-132760.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.